DOI: 10.1097/01.COT.0000444386.49340.3f

,  

Issn Print: 0276-2234

Publication Date: 2014/02/25


Print

Combination Treatments Improve Outcomes in Problematic GI Cancers

Robert H. Carlson

    loading  Checking for direct PDF access through Ovid

Excerpt

Three trials of combination therapies presented at the Gastrointestinal Cancers Symposium reported improvements in prognosis for patients diagnosed with historically difficult-to-treat cancers. All three were discussed during a presscast news conference in advance of the meeting.
In gastroesophageal junction and gastric adenocarcinomas, the Phase III RAINBOW study showed increased survival with use of ramucirumab plus paclitaxel when compared with paclitaxel alone, for patients with metastatic disease that had progressed after first-line chemotherapy.
In pancreatic cancer, updated results of a Phase II study evaluating a new cancer vaccine combination in patients with previously treated, metastatic disease showed that immunotherapy can be effective.
And in neuroendocrine tumors, a combination of capecitabine and temozolomide was associated with a response rate of 43 percent and a 54 percent rate of stable disease in patients with treatment-resistant, metastatic disease.
    loading  Loading Related Articles